TGFB1 and Thrombocytopenia: In thrombocytopenic MF patients that were ineligible for ruxolitinib therapy, in a phase I clinical trial of AVID200 therapy led to substantial increases in platelet numbers and reduction of TGFβ1 serum levels indicating that TGFβ1 plays a pivotal role in MF associated thrombocytopenia which can be reversed with AVID200 therapy (59).